MAIA Biotechnology (MAIA) announced the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the ...

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing ...

CHICAGO, March 20, 2025--(BUSINESS WIRE)--MAIA Biotechnology ... preclinical data for its lead proprietary telomere-targeting THIO dimer in the peer-reviewed scientific journal Naunyn ...

CHICAGO, March 19, 2025--(BUSINESS WIRE)--MAIA Biotechnology ... name for its lead molecule THIO, a telomere-targeting anticancer agent in clinical development as a first-in-class treatment ...

Novel THIO dimer shows promise as a new compound with a dual mechanism of action for enhancing standard cancer treatments and overcoming resistance MAIA Biotechnology, Inc., (NYSE American ...

Chicago-based Maia Biotechnology said this week that its lead drug candidate, THIO, has gained its generic name, and preclinical data on a different form of the cancer drug suggests it could ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American ... name for its lead molecule THIO, a telomere-targeting anticancer agent in clinical development as a first-in-class treatment ...

MAIA Biotechnology, Inc., (NYSE American ... name for its lead molecule THIO, a telomere-targeting anticancer agent in clinical development as a first-in-class treatment for advanced non-small ...

In other recent news, MAIA Biotechnology has expanded its Phase 2 THIO-101 trial to include additional patients with advanced non-small cell lung cancer (NSCLC). This expansion aims to evaluate ...